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Abstract
Background: The aim of the present study was to evaluate the protective effects of the 4-anilinoquinazoline derivative
PD153035 on cardiac ischemia/reperfusion and mitochondrial function.
Methodology/Principal Findings: Perfused rat hearts and cardiac HL-1 cells were used to determine cardioprotective
effects of PD153035. Isolated rat heart mitochondria were studied to uncover mechanisms of cardioprotection. Nanomolar
doses of PD153035 strongly protect against heart and cardiomyocyte damage induced by ischemia/reperfusion and
cyanide/aglycemia. PD153035 did not alter oxidative phosphorylation, nor directly prevent Ca2+ induced mitochondrial
membrane permeability transition. The protective effect of PD153035 on HL-1 cells was also independent of AKT
phosphorylation state. Interestingly, PD153035 activated K+ transport in isolated mitochondria, in a manner prevented by
ATP and 5-hydroxydecanoate, inhibitors of mitochondrial ATP-sensitive K+ channels (mitoKATP). 5-Hydroxydecanoate also
inhibited the cardioprotective effect of PD153035 in cardiac HL-1 cells, demonstrating that this protection is dependent on
mitoKATP activation.
Conclusions/Significance: We conclude that PD153035 is a potent cardioprotective compound and acts in a mechanism
involving mitoKATP activation.
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Introduction
Ischemic heart disease is a global health concern, and the
development of new strategies to protect the heart has attracted
significant attention. Mitochondrial damage is a well known
consequence of heart ischemia, and many cardioprotective drugs
are targeted to this organelle [1–4]. Ischemia followed by reperfusion
leads to increases in intracellular Ca2+ levels and oxidative stress,
which promotes the oxidation of inner mitochondrial membrane
proteins, resulting in non-selective permeabilization of this mem-
brane. This process is known as the mitochondrial permeability
transition [5,6]. Inhibition of the permeability transition during
reperfusion results in substantial prevention of structural cardiac
damage and improvements of cardiac function [2–4,7–9].
In addition to undergoing damage during ischemia, mitochon-
dria have been uncovered as important sites for signaling processes
related to ischemia and myocardial protection. Ischemic precon-
ditioning, a protocol in which short periods of ischemia protect
against subsequent longer damaging ischemic periods [10],
involves changes in mitochondrial reactive oxygen species release
and ion transport [11–14]. More specifically, activation of ATP-
sensitive K+ channels in mitochondria (mitoKATP) is a necessary
step for cardioprotection promoted by ischemic preconditioning
[15,16]. MitoKATP activation is also necessary for cardioprotection
promoted by adenosine, respiratory chain inhibitors and some
anesthetics [2,12,17–19]. Activation of phosphoinositide 3 kinase
(PI3K)-AKT has been implicated as an upstream event in the
mitoKATP activation in preconditioning [20,21].
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Epidermal growth factor (EGF) tyrosine kinase 2 is an important
survival factor for human cardiomyocytes [22], and EGF receptor
tyrosine kinase activity has been also implicated in the pathogen-
esis of cardiovascular disorders [23–27]. Here, we tested the
possible cardioprotective effects of PD153035, a 4-anilinoquinazo-
line derivative developed as an EGF receptor tyrosine kinase
inhibitor [28]. We found that PD153035 is a potent cardiopro-
tective agent in perfused rat hearts and cardiac HL-1 cells.
Interestingly, we demonstrate that cardioprotection by PD153035
is associated with mitoKATP activation, and provide evidence that
this drug may be a direct agonist of this channel.
Materials and Methods
Materials and laboratory animals
All reagents used were of analytical grade or better, and
deionized water was used for all aqueous solutions. PD153035 [4-
N-(39-bromophenylamino)-6,7-dimethoxyquinazoline hydrochlo-
ride] (.99% purity) was synthesized as previously described
[29]. PD153035 solutions were prepared daily, in DMSO.
Male Wistar rats were obtained from the UNICAMP Central
Animal Breeding Facilities (Campinas, Brazil). Protocols used were
approved by the local Committee for Ethics in Animal Research,
and conformed with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
Isolated heart preparations
Male Wistar rats weighing 200–250 g were anesthetized with
pentobarbital sodium (50 mg/kg i.p.) and placed on a tempera-
ture-controlled surgical table. After injection of heparin sodium
(500 U/kg i.v.), hearts were removed [30], and the aorta was
cannulated with a 20-gauge catheter positioned ,2 mm above the
coronary ostia. Hearts were perfused with HEPES buffer
(137 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2,
6 mM glucose, 2 U/L insulin, 0.0001% xylocaine, 1000 U/L
heparin and 20 mM HEPES, pH 7.4) bubbled with 100% O2 at a
constant pressure of 70 mmHg, at 37uC. Where indicated,
PD153035 was added to the perfusion buffer and present during
the full perfusion protocol, from the stabilizing period until the end
of the reperfusion. Control hearts were perfused with the same
quantity as perfused hearts of DMSO, which remained under
0.01%. Left ventricular diastolic pressure was kept constant at
5 mmHg and continuously monitored (WinDaq Software, DA-
TAQ Instruments, Inc., Akron, OH, USA) through a water-filled
latex balloon inserted into the lumen of the left ventricle via the left
atrium. The distal end of the balloon-attached catheter was
connected to a pressure transducer for intraventricular pressure
monitoring. Ventricular function was determined from left
ventricular pressure measurements.
Cell cultures
Murine atrial HL-1 cells were developed and kindly donated by
Prof. William C. Claycomb (Louisiana State University, New
Orleans, LO, USA). These cells maintain their cardiac phenotype
during extended passages, present ordered myofribrils, cardiac-
specific junctions and several voltage-dependent currents that are
characteristic of a cardiac myocyte phenotype [31]. Furthermore,
HL-1 cells present conserved preconditioning mechanisms depen-
dent on protein kinase C and K+ channel activation [32] and
ischemic damage dependent on the mitochondrial permeability
transition [8]. For routine growth, HL-1 cells were maintained in
T-75 flasks at 37uC in an atmosphere of 5% CO2 in Claycomb
medium (JRH Biosciences, Lenexa, KS, USA) supplemented with
0.1 mM norepinephrine, 100 U/mL and 100 mg/mL penicillin/
streptomycin, 2 mM glutamine and 10% fetal bovine serum.
Experiments were conducted when the cultures reached 100%
confluence, after trypsinization and resuspension of the cells in a
standard buffer (pH = 7.4) containing (in mmol/L): NaCl, 137;
Hepes, 5; glucose, 22; taurine, 20; creatine, 5; KCl, 5.4; MgCl2, 1;
sodium pyruvate, 5 and CaCl2, 1 [8,14]. Cells were maintained in
suspension during the experimental protocols, at a concentration
,1.56106 cells/mL.
Simulated ischemia/reperfusion (cyanide/aglycemia) in
cultured HL-1 cells
Ischemia was simulated by metabolic inhibition and substrate
deprivation using 10 mM potassium cyanide and 2 mM 2-
deoxyglucose, added to standard buffer devoid of glucose and
pyruvate. The joint presence of cyanide and deoxyglucose inhibits
oxygen consumption in these cells by at least 95% (H.T. Facundo
and A.J. Kowaltowski, unpublished observations), in a reversible
manner. HL-1 myocytes were incubated under cyanide/aglycemia
during 60 min followed by 5 min centrifugation and re-suspension
of the cell pellet in control buffer for simulated reperfusion. Where
indicated, 10 nM PD153035, 0.05% DMSO (controls) and/or
60 mM 5HD were present during the 20 min pre-incubation
period before cyanide/aglycemia. Control HL-1 myocytes were
incubated with standard buffer solution the entire experimental
period, and submitted only to the centrifugations in order to
ensure that all cells undergo equal mechanical damage [8,14].
Cell viability
Cell viability was assessed by relative fluorescence of 50 mM
ethidium bromide (Sigma-Aldrich) using a Hitachi F4500
spectrofluorometer at excitation and emission wavelengths of
365 and 580 nm, respectively [33]. Cells were treated with
0.005% digitonin at the end of each experiment to promote 100%
cell permeabilization. The auto-fluorescence of ethidium bromide
was subtracted from total fluorescence in the presence of cells,
ethidium bromide or digitonin. Data are expressed as the
percentage of total cells [8,14].
Isolation of rat heart mitochondria
Heart mitochondria were isolated from adult male Wistar rats
as described by Kowaltowski et al. [34]. Mitochondria were kept
over ice until the experiments were initiated. To ensure mitoKATP
activity and its pharmacological regulation, all experiments using
isolated mitochondria were conducted within 1 h of isolation
[14,35].
Oxygen uptake measurements
Oxygen consumption was measured in a 1.4 mL temperature-
controlled vessel equipped with a magnetic stirrer, using a Clark-
type electrode (Yellow Spring Instruments Company). Mitochon-
dria (0.5 mg/mL) were incubated in medium (37uC) containing
125 mM sucrose, 65 mM KCl, 10 mM HEPES, pH 7.2, 2.5 mM
KH2PO4 and 0.4 mM EGTA. Respiratory chain activity was
maintained using a mixture of NAD-linked substrates (malate,
glutamate, a-ketoglutarate and pyruvate, 1.25 mM each) or
2.5 mM succinate plus 2 mM rotenone.
Mitochondrial Ca2+ transport
Variations in medium free Ca2+ concentrations were examined
by measuring changes in the absorbance spectrum of arsenazo III
(40 mM) using an SLM Aminco DW2000 spectrophotometer
Cardioprotection by PD153035
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(SLM Instruments, Inc., Urbana, USA) set at the 675–685 nm
wavelength pair [36].
Western Blots
Protein fractions from HL-1 myocytes cells were subjected to
12% SDS-PAGE and transferred to a nitrocellulose membrane.
Blots were blocked with 5% bovine serum albumin (BSA) in TBS-
T (0.05% Tween 20 in 50 mM Tris–HCl (pH 7.4), 150 mM
NaCl) and incubated overnight with a rabbit polyclonal antibody
specific for mouse AKT (Calbiochem) at 0.2 mg/mL or mouse
phospho-Akt (Cell Signaling) at 0.1 mg/mL in 0.1% BSA TBS-T.
After primary antibody incubation, the blots were washed and
incubated with peroxidase-conjugated secondary antibody (10 ng/
mL, Calbiochem). The signal was developed with the SuperSignal
West Pico Chemiluminescent Substrate kit (Pierce Biotechnology,
Rockford, IL). Image densitometry was performed using Image J
and Image Quant softwares.
Mitochondrial swelling
Mitochondrial swelling was estimated from the decrease in
absorbance of the mitochondrial suspension measured at 520 nm
using a temperature-controlled SLM Aminco DW-2000 spectro-
photometer equipped with continuous stirring at 37uC. Swelling of
freshly isolated mitochondria was measured soon after their
addition to K+-rich hyposmotic buffers. This procedure allows for
a magnified measurement of K+ uptake due to prior K+ depletion
during the mitochondrial isolation procedure [34]. Where
indicated, experiments were conducted in media in which KCl
was substituted by LiCl, and the solution pH was corrected using
NaOH, as a control for K+-specificity. Mitochondrial light
scattering changes 40 sec after the addition in the experimental
buffer were used to generate the data shown in the figure.
Data analysis
Experiments depict typical traces or averages6standard errors of the
mean from at least 3 identical repetitions using different preparations.
Data were compared by one-way ANOVA followed by Tukey’s post-
hoc test performed by OriginPro 7.5 SRO (OriginLab Corporation,
Northampton, MA, USA). When one parameter was compared
between two groups, Student’s t-test was used.
Results
Perfused rat hearts were pre-treated with different concentrations
of PD153035 and submitted to 40 min ischemia followed by
reperfusion. Figures 1A–D show representative left ventricular
pressure measurements in these perfused hearts. Upon global
ischemia, the contractile function of the isolated rat hearts ceased
within a few cycles (Panel A). Following reperfusion, spontaneous
beating is resumed, but with increases in diastolic pressures and
decreased systolic performance, as indicated by the marked reduction
in the developed pressure. On the other hand, hearts pre-treated with
increasing PD153035 concentrations (10 pM, Panel B; 1 nM,
Panel C or 100 nM, Panel D) presented significantly less increases
in the diastolic pressure and reductions in the systolic performance.
Figures 1E–F shows average left ventricular developed pressures
(Panel E) and diastolic pressures (Panel F) in hearts submitted to
ischemia/reperfusion in the presence of 10 pM (m), 1 nM (#) or
100 nM PD153035 (X). Compared to controls (%), PD153035
treatment strikingly improved cardiac function, with a maximal effect
observed at 1 nM.
The cardioprotective effects of PD153035 were confirmed using
a cultured cell model involving murine cardiac HL-1 cells, which
allows for direct measurements of cell death [14,31]. In these cells,
metabolic inhibition promoted by treatment with cyanide and 2-
deoxyglucose, followed by return to control conditions, mimics
cardiac ischemia/reperfusion (Figure 2A, e). Indeed, cell death
occurs predominantly after the return of metabolic activity (the
simulated reperfusion period which begins where indicated by the
second arrow) [14]. The presence of 10 nM PD153035 in the
preincubation media completely abrogated cell death promoted by
cyanide/aglycemia in cardiac HL-1 cells (m), while an equal
quantity of the compound’s solvent, DMSO (0.05%), had no
protective effect (&).
Under these conditions, HL-1 cell death is dependent on the
induction of the permeability transition, a Ca2+-induced non-selective
inner mitochondrial membrane permeabilization [5,6,8]. In order to
verify if inhibition of mitochondrial permeability transition was
involved in the cardioprotective effects of PD153035, we tested if this
compound could inhibit this process in isolated rat heart mitochon-
dria (Figure 3). Mitochondria are able to take up large quantities of
Ca2+, followed by release of this ion due to non-selective
permeabilization (line a). The presence of the permeability transition
inhibitor cyclosporin A prevents Ca2+ release without affecting uptake
(line b). On the other hand, PD153035 did not inhibit either Ca2+
uptake or release at nanomolar (lines c–f) or micromolar concentra-
tions (up to 40 mM, results not shown).
Since mitochondria are intimately involved in ischemic cardio-
protection [1–3,7,8,12] we also investigated if PD153035 affected
respiration and oxidative phosphorylation in these organelles. We
found that nanomolar PD153035 concentrations did not affect
mitochondrial respiratory rates in the presence (state 3) or absence
(state 4) of oxidative phosphorylation using NADH-linked substrates
(Table 1) or succinate plus rotenone (results not shown). PD153035
also did not affect ATP synthesis, as determined by the lack of change
in respiratory control and ADP/O ratios.
An important phenomenon involved in cardioprotection in both
ischemic/reperfused hearts and cyanide-treated/aglycemic car-
diomyocytes is the activation of mitochondrial ATP-sensitive K+
channels (mitoKATP) [2,37]. Indeed, we found that cytoprotection
promoted by PD153035 could be completely abrogated by
mitoKATP inhibitor 5-hydroxydecanoate (5HD), which had no
effect on the survival of control cells or cyanide/aglycemic cells not
treated with PD153035 (Figure 2B). This finding leads to the
hypothesis that PD153035 could activate mitoKATP. To further
study the activation of mitoKATP under our experimental
conditions, we tested if this channel could be activated via
intracellular signaling involving the PI3K-AKT cascade [20,21] or
directly via activation of mitoKATP. We found that AKT levels
were similar under all conditions, while pAKT (the active form)
decreased to undetectable levels with cyanide/aglycemia. No
evidence for AKT activation by PD153035 treatment was
obtained either in control or cyanide-treated/aglycemic cardio-
myocytes (Figure 4).
In order to test if PD153035 could directly activate mitoKATP,
we added this compound directly to isolated mitochondria and
followed organellar swelling due to K+ uptake, which is
accompanied by the uptake of phosphate and water [37]. Under
these conditions, mitoKATP agonist diazoxide (DZX) reversed
ATP-inhibited mitochondrial swelling in K+ media, in a manner
inhibited by 5HD (results not shown; [16]). Interestingly,
PD153035 partially reversed the inhibitory effect of ATP on
mitochondrial swelling (see Figure 5A for typical traces and 5B
for averages). More strikingly, PD153035 increased swelling under
control conditions in K+, but not Li+, media (Figure 5B). This
indicates that PD153035 increases overall mitochondrial ATP-
sensitive K+ transport activity. The activation was prevented by
mitoKATP inhibitor 5HD (Figure 5B), which does not affect
Cardioprotection by PD153035
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swelling under control conditions [16]. The equivalent concen-
tration of PD153035 solvent DMSO (0.1%) had no significant
effect on mitochondrial swelling (not shown).
Discussion
We demonstrate here that the 4-anilinoquinazoline derivative
PD153035 is a potent cardioprotective agent capable of preventing
reperfusion injury when used in the nanomolar concentration range
(Figure 1). Furthermore, nanomolar concentrations of PD153035
completely prevented cardiac HL-1 cell death promoted by
metabolic inhibition followed by a return of oxidative metabolism
(Figure 2), a situation in which cellular damage occurs through
mechanisms similar to those found in ischemia/reperfusion [8,14].
Cytoprotection by PD153035 was completely reversed by 5HD
(Figure 2B), an antagonist of mitoKATP channels. These channels
Figure 1. PD153035 improves cardiac function after ischemia/reperfusion. Panels A–D: Perfused rat hearts were submitted to left
ventricular pressure measurements after 15 min stabilizing perfusion, as described in the Methods section. PD153035 was present at 10 pM, 1 nM or
100 nM (Panels B, C and D, respectively) during the full experimental period. Panel A shows hearts in the absence of PD153035. After 10 min, the
hearts were submitted to 40 min ischemia by interruption of coronary flow, followed by 35 min reperfusion. Data are representative traces of 3
similar repetitions. LVP: Left ventricular pressure. Panels E–F: Averages6SEM of 3 experiments conducted under the conditions of Panels A–D. DLVP:
developed left ventricular pressure; DP: diastolic pressure. Values for 10 pM, 1 nM and 100 nM PD153035 concentrations were significantly different
from controls at 85 min (p,0.05).
doi:10.1371/journal.pone.0010666.g001
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are well known mediators of ischemic cardioprotection promoted
by preconditioning or other known cardioprotective drugs [2,12].
In fact, when tested in isolated mitochondria, PD153035 activated
K+ uptake in an ATP-sensitive, 5HD-inhibited manner (Figure 5).
No effects of PD153035 were observed in media in which K+ ions
were substituted by Li+. Together, these data suggest that
PD153035 directly activates a K+-selective, ATP-sensitive trans-
port typical of mitoKATP. On the other hand, we found no
significant effect of PD153035 on oxidative phosphorylation
(Table 1), mitochondrial Ca2+ uptake and retention (Figure 3)
or AKT phosphorylation (Figure 4). These results indicate that
the direct activation of mitoKATP by PD153035 can explain
cardioprotection by this compound, although cardioprotection
may also involve increases of this channel’s activity by AKT-
independent intracellular signaling events initiated by this
compound’s inhibitory effect on EGF receptor tyrosine kinase.
Interestingly, although EGF tyrosine kinase 2 is a survival factor
for human cardiomyocytes [22], not all inhibitors of this kinase
present overt cardiotoxicity [38].
MitoKATP are highly K
+-selective channels, which promote
uptake of this ion down the mitochondrial electrochemical
gradient. Transport through these channels is inhibited physio-
logically by ATP and ADP, and activated by GTP, GDP and UDP
[39,40]. Many pharmacological agonists and antagonists for these
channels have been studied [41]. In particular, diazoxide (DZX) is
widely used as a mitoKATP agonist due to its selectivity toward
mitochondrial, and not plasma membrane, ATP-sensitive K+
channels [37]. DZX is capable of overcoming the inhibitory effect
of ATP or ADP on mitoKATP. Similarly, 5-hydroxydecanoate
(5HD) is a mitoKATP antagonist with no measurable effect on
sarcolemal K+ transport [16]. 5HD prevents the agonistic effect of
DZX and other physiological and pharmacological mitoKATP
activators.
The mechanisms through which mitoKATP promotes ischemic
cardioprotection are complex and still remain to be completely
understood. MitoKATP activity is capable of preventing loss of
cellular high energy phosphates, resulting in a more favorable
energetic state [42,43]. The channel activation also prevents
excessive Ca2+ uptake in mitochondria exclusively during
ischemia, when this uptake is supported by ATP hydrolysis by
the ATPsynthase [42,44,45]. This inhibition of Ca2+ uptake, in
association with a decrease in mitochondrial oxidative stress also
promoted by mitoKATP activity, results in prevention of
mitochondrial permeability transition and ensuing loss of orga-
nellar functionality [2,8].
Although DZX is a useful tool for in vitro mitoKATP studies, this
drug has limited applicability for in vivo myocardial protection,
since its effect on pancreatic islet K+ channel transport results in
Figure 2. PD153035 protects against cardiac cell damage promoted by cyanide/aglycemia. Panel A: Cardiac HL-1 cells were
preincubated in standard media (see Materials and Methods) containing 10 nM PD153035 (m), the equivalent concentration of PD153035 solvent
DMSO (0.05%;&) or no further additions (#,e). Where indicated, all cells except controls (#) were treated with 10 mM K-cyanide (CN) and 2 mM 2-
deoxyglucose (2-DG). All cells were submitted to equal centrifugations and media changes where indicated by the arrows. Panel B represents
average cellular viability at 140 min. HL-1 cells were treated as described in Panel A. Where indicated, cells were preincubated in the presence of
60 mM 5-hydroxydecanoate (5HD) and/or 10 nM PD153035 (PD). Data represent average cell viability (see Materials and Methods) of 5
experiments6SEM. Data in Panels A and B represent separate experimental groups in which baseline measurements are not significantly distinct.
*p,0.05 relative to ‘‘control’’ and ‘‘CN+2-DG+PD153035’’ at the respective time point. #p,0.05 relative to ‘‘CN+2-DG’’ at the respective time point.
doi:10.1371/journal.pone.0010666.g002
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decreases in insulin secretion [46]. Furthermore, a desirable
mitoKATP agonist should be active at very low concentrations,
preferably less than the micromolar range necessary for DZX to
activate mitoKATP. Interestingly, Prada et al [47] recently showed
that treatment with PD153035 reduces levels of inflammatory
markers and improves glucose tolerance, insulin sensitivity and
signaling in high-fat diet-fed mice.
The direct activation of mitoKATP by PD153035 in isolated
mitochondria was a surprising finding of the present study, since
this compound bears no strong structural resemblance with any
known mitoKATP agonist [12]. On the other hand, PD153035 is a
kinase inhibitor due to its ability to prevent ATP binding to these
enzymes [28]. Since mitoKATP is also inhibited by ATP and ADP,
it is tempting to speculate that PD153035 activates the channel by
interfering with binding of these nucleotides to the protein.
Interestingly, PD153035 is, to our knowledge, the only compound
capable of activating mitochondrial K+ uptake in the absence of
added ATP or ADP, possibly due to displacement of endogenous
adenine nucleotides. This unique characteristic may render the
drug more effective as an agonist.
4-anilinoquinazoline derivatives are currently believed to be
viable clinical tools for control of proliferative diseases such as
cancer and psoriasis, and act by inhibiting the EGF receptor
Figure 3. PD153035 does not decrease mitochondrial Ca2+
uptake, nor prevent permeability transition. Isolated rat heart
mitochondria (RHM; 0.5 mg/mL) were incubated in 125 mM sucrose,
65 mM KCl, 10 mM HEPES, 2.5 mM KH2PO4, 40 mM arsenazo III,
1.25 mM malate, 1.25 mM glutamate, 1.25 mM pyruvate and 1.25 mM
a-ketoglutarate, pH 7.2 (KOH). Ca2+ was added where indicated in four
consecutive boluses of 10 mM, totaling 40 mM. Line a represents a
control experiment with no further additions. Line b represents an
experiment conducted in the presence of 1 mM cyclosporin A. Lines c–f
represent experiments conducted in the presence of 1 nM, 10 nM,
30 nM and 100 nM PD153035, sequentially. Data are representative
traces of 3 similar repetitions.
doi:10.1371/journal.pone.0010666.g003
Table 1. PD153035 does not change mitochondrial respiratory parameters.
Control PD153035
State 3 respiratory rate (nmol O26mg protein
216min21) 113.468.9 109.967.3
State 4 respiratory rate (nmol O26mg protein
216min21) 16.2161.59 16.9361.27
Respiratory control ratio (state 3/state 4) 7.2560.46 6.5860.23
ADP/O ratio 2.0660.14 2.1460.12
Rat heart mitochondria were incubated in 125 mM sucrose, 65 mM KCl, 10 mM HEPES, 2.5 mM KH2PO4, 0.4 mM EGTA, 1.25 mM malate, 1.25 mM glutamate, 1.25 mM
pyruvate and 1.25 mM a-ketoglutarate, pH 7.2 (KOH), in the presence of 10 nM PD153035 or the equivalent concentration of PD153035 solvent DMSO (0.1%) (Control),
as indicated. ADP (250 mM) and 1 mg/mL oligomycin were added to achieve state 3 and 4 respiratory rates, respectively. Respiration was measured using a Clark-type
electrode, and respiratory parameters were calculated as described in Materials and Methods. None of the values obtained in the presence of PD153035 are significantly
different from controls (four independent preparations, experiments performed in triplicate).
doi:10.1371/journal.pone.0010666.t001
Figure 4. PD153035 does not alter AKT phosphorylation.
Cardiac HL-1 cells were preincubated in standard media (see Materials
and Methods) containing 10 nM PD153035 or the equivalent concentra-
tion of PD153035 solvent DMSO during 20 min. 10 mMK-cyanide (CN) and
2 mM 2-deoxyglucose (2-DG) were then added under the conditions of
Figure 2, where indicated. After 60 min, suspension proteins were
extracted and AKT and pAKT levels were estimated by immunoblotting.
*p,0.01 relative to the conditions in the absence of ‘‘CN+2-DG’’.
doi:10.1371/journal.pone.0010666.g004
Cardioprotection by PD153035
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family of tyrosine kinases [48–51]. Indeed, 11C-PD153035 can be
used as an EGF receptor tracer in whole-body examinations for
cancerous tissue, and has already been successfully tested in
humans [52]. Quinazoline derivatives also act as antagonists of a-
adrenergic receptors and may be used as anti-hypertensives [53].
Our results uncover another potential application for PD153035,
as a powerful protective agent in ischemic heart disease.
Furthermore, our results demonstrate that this compound is
capable of substantially activating mitochondrial ATP-sensitive K+
uptake.
Acknowledgments
The authors gratefully acknowledge the expert technical support of Edilene
S. Santos and Elisangela J. Gomes. HL-1 cells were kindly donated by Prof.
William Claycomb (Louisiana State University, New Orleans, LO, USA).
Author Contributions
Conceived and designed the experiments: AJK AEV KGF RFC.
Performed the experiments: RAC RMM SAR FMC CCCdS. Analyzed
the data: RAC RMM AJK AEV KGF RFC. Contributed reagents/
materials/analysis tools: SAR RR AJK AEV KGF RFC. Wrote the paper:
AJK KGF RFC.
References
1. Marczin N, El-Habashi N, Hoare GS, Bundy RE, Yacoub M (2003)
Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential
and basic mechanisms. Arch Biochem Biophys 420: 222–236.
2. Facundo HT, Fornazari M, Kowaltowski AJ (2006) Tissue protection mediated
by mitochondrial K+ channels. Biochim Biophys Acta 1762: 202–212.
3. Halestrap AP, Clarke SJ, Khaliulin I (2007) The role of mitochondria in
protection of the heart by preconditioning. Biochim Biophys Acta 1767:
1007–1031.
4. Baines CP (2009) The mitochondrial permeability transition pore and ischemia-
reperfusion injury. Basic Res Cardiol 104: 181–188.
5. Crompton M (1999) The mitochondrial permeability transition pore and its role
in cell death. Biochem J 341: 233–249.
6. Kowaltowski AJ, Castilho RF, Vercesi AE (2001) Mitochondrial permeability
transition and oxidative stress. FEBS Lett 495: 12–15.
7. Duchen MR, McGuinness O, Brown LA, Crompton M (1993) On the
involvement of a cyclosporin A sensitive mitochondrial pore in myocardial
reperfusion injury. Cardiovasc Res 27: 1790–1794.
8. Facundo HT, de Paula JG, Kowaltowski AJ (2005) Mitochondrial ATP-sensitive
K+ channels prevent oxidative stress, permeability transition and cell death.
J Bioenerg Biomembr 37: 75–82.
9. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, et al. (2008) Effect of
cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med
359: 473–481.
10. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a
delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136.
11. Vanden Hoek TL, Becker LB, Shao Z, Li C, Schumacker PT (1998) Reactive
oxygen species released from mitochondria during brief hypoxia induce
preconditioning in cardiomyocytes. J Biol Chem 273: 18092–18098.
12. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P (2003) Mitochondrial
potassium transport: the role of the mitochondrial ATP-sensitive K+ channel in
cardiac function and cardioprotection. Biochim Biophys Acta 1606: 1–21.
13. Gross GJ, Peart JN (2003) KATP channels and myocardial preconditioning: an
update. Am J Physiol Heart Circ Physiol 285: H921–H930.
14. Facundo HT, Carreira RS, de Paula JG, Santos CC, Ferranti R, et al. (2006)
Ischemic preconditioning requires increases in reactive oxygen release
independent of mitochondrial K+ channel activity. Free Radic Biol Med 40:
469–479.
15. Auchampach JA, Grover GJ, Gross GJ (1992) Blockade of ischaemic
preconditioning in dogs by the novel ATP dependent potassium channel
antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 26: 1054–1062.
16. Jabu˚rek M, Yarov-Yarovoy V, Paucek P, Garlid KD (1998) State-dependent
inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxyde-
canoate. J Biol Chem 273: 13578–13582.
17. Mubagwa K, Flameng W (2001) Adenosine, adenosine receptors and
myocardial protection: an updated overview. Cardiovasc Res 52: 25–39.
18. Cohen MV, Baines CP, Downey JM (2000) Ischemic preconditioning: from
adenosine receptor to KATP channel. Annu Rev Physiol 62: 79–109.
19. Wojtovich AP, Brookes PS (2009) The complex II inhibitor atpenin A5 protects
against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP
channels. Basic Res Cardiol 104: 121–129.
Figure 5. PD153035 increases mitochondrial ATP-sensitive K+ transport. Isolated rat heart mitochondria (RHM; 0.5 mg/mL) were suspended
in 100 mM KCl, 5 mM HEPES, 2 mM Pi, 1 mM MgCl2, 0.1 mM EGTA, 1 mg/mL oligomycin and 10 mM succinate, pH 7.4 (KOH), and light scattering
changes were recorded over the first 40 seconds. Where indicated, 200 mM ATP, 10 nM PD153035, 20 mM DZX and/or 60 mM 5-HD were present.
Control experiments were conducted in the presence of the equivalent concentration of PD153035 solvent DMSO (0.1%). Panel A depicts
representative traces, while Panel B shows average6SEM swelling relative to control of 8 experimental repetitions. The hatched column represents
an experiment in which KCl was substituted by LiCl. *p,0.01 versus control; #p,0.01 versus PD. The effect of PD153035 in Li+ media was compared
to swelling in Li+ media in the absence of this drug. Incubations in Li+ media resulted in 88.664.0% of the swelling observed in K+ media.
doi:10.1371/journal.pone.0010666.g005
Cardioprotection by PD153035
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10666
20. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, et al. (2005) Protein
kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ
Res 97: 329–336.
21. Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning
and postconditioning. Cardiovasc Res 70: 240–253.
22. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, et al. (2002) ErbB2 is
essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459–465.
23. Yamazaki T, Komuro I, Yazaki Y (1998) Signalling pathways for cardiac
hypertrophy. Cell Signal 10: 693–698.
24. Suc I, Meilhac O, Lajoie-Mazenc I, Vandaele J, Ju¨rgens G, et al. (1998)
Activation of EGF receptor by oxidized LDL. FASEB J 12: 665–671.
25. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, et al. (2002)
Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by
epidermal growth factor receptor antisense. Circulation 106: 909–912.
26. Nuntharatanapong N, Chen K, Sinhaseni P, Keaney JF, Jr. (2005) EGF
receptor-dependent JNK activation is involved in arsenite-induced p21Cip1/
Waf1 upregulation and endothelial apoptosis. Am J Physiol Heart Circ Physiol
289: H99–H107.
27. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological
and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol
292: C82–97.
28. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, et al. (1994) A
specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science
265: 1093–1095.
29. Rocco SA, Barbarini JE, Rittner R (2004) Syntheses of some 4-anilinoquinazo-
line derivatives. Synthesis 3: 429–435.
30. Domingos PP, Fonseca PM, Nadruz W, Jr., Franchini KG (2002) Load-induced
focal adhesion kinase activation in the myocardium: role of stretch and
contractile activity. Am J Physiol Heart Circ Physiol 282: H556–H564.
31. Claycomb WC, Lanson NA, Jr., Stallworth BS, Egeland DB, Delcarpio JB, et al.
(1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic
characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 95:
2979–2984.
32. Seymour EM, Wu SY, Kovach MA, Romano MA, Traynor JR, et al. (2003)
HL-1 myocytes exhibit PKC and KATP channel-dependent delta opioid
preconditioning. J Surg Res 114: 187–194.
33. Karsten U (1980) Fluorometric estimation of dead cells in cell suspensions.
Experientia 36: 263–264.
34. Kowaltowski AJ, Seetharaman S, Paucek P, Garlid KD (2001) Bioenergetic
consequences of opening the ATP-sensitive K+ channel of heart mitochondria.
Am J Physiol Heart Circ Physiol 280: H649–H657.
35. Facundo HT, de Paula JG, Kowaltowski AJ (2007) Mitochondrial ATP-sensitive
K+ channels are redox-sensitive pathways that control reactive oxygen species
production. Free Radic Biol Med 42: 1039–1048.
36. Scarpa A (1979) Measurements of cation transport with metallochromic
indicators. Methods Enzymol 56: 301–338.
37. Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, et al.
(1997) Cardioprotective effect of diazoxide and its interaction with mitochon-
drial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ
Res 81: 1072–1082.
38. Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, et al. (2007) Activation of
AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine
kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA 104:
10607–10612.
39. Garlid KD, Paucek P (2003) Mitochondrial potassium transport: the K+ cycle.
Biochim Biophys Acta 1606: 23–41.
40. Mironova GD, Negoda AE, Marinov BS, Paucek P, Costa AD, et al. (2004)
Functional distinctions between the mitochondrial ATP-dependent K+ channel
(mitoKATP) and its inward rectifier subunit (mitoKIR). J Biol Chem 279:
32562–32568.
41. Szewczyk A, Skalska J, Głab M, Kulawiak B, Malin´ska D, et al. (2006)
Mitochondrial potassium channels: from pharmacology to function. Biochim
Biophys Acta 1757: 715–720.
42. Belisle E, Kowaltowski AJ (2002) Opening of mitochondrial K+ channels
increases ischemic ATP levels by preventing hydrolysis. J Bioenerg Biomembr
34: 285–298.
43. Dos Santos P, Kowaltowski AJ, Laclau MN, Seetharaman S, Paucek P, et al.
(2002) Mechanisms by which opening the mitochondrial ATP- sensitive K+
channel protects the ischemic heart. Am J Physiol Heart Circ Physiol 283:
H284–H295.
44. Murata M, Akao M, O’Rourke B, Marba´n E (2001) Mitochondrial ATP-
sensitive potassium channels attenuate matrix Ca2+ overload during simulated
ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 89:
891–898.
45. Ishida H, Hirota Y, Genka C, Nakazawa H, Nakaya H, et al. (2001) Opening of
mitochondrial KATP channels attenuates the ouabain-induced calcium overload
in mitochondria. Circ Res 89: 856–858.
46. Doyle ME, Egan JM (2003) Pharmacological agents that directly modulate
insulin secretion. Pharmacol Rev 55: 105–131.
47. Prada PO, Ropelle ER, Moura˜o RH, de Souza CT, Pauli JR, et al. (2009) An
EGFR Tyrosine-Kinase Inhibitor (PD153035) Improves Glucose Tolerance and
Insulin Action in High-Fat Diet-Fed Mice. Diabetes 58: 2910–2919.
48. Fry DW (1999) Inhibition of the epidermal growth factor receptor family of
tyrosine kinases as an approach to cancer chemotherapy: progression from
reversible to irreversible inhibitors. Pharmacol Ther 82: 207–218.
49. Ciardiello F (2000) Epidermal growth factor receptor tyrosine kinase inhibitors
as anticancer agents. Drugs 60 Suppl 1: 25–32.
50. Rewcastle GW, Denny WA, Showalter HD (2000) Synthesis of 4-(phenylami-
no)pyrimidine derivatives as ATP-competitive protein kinase inhibitors with
potential for cancer chemotherapy. Curr Org Chem 4: 679–706.
51. Arteaga CL, Baselga J (2003) Clinical trial design and end points for epidermal
growth factor receptor-targeted therapies: implications for drug development
and practice. Clin Cancer Res 9: 1579–1589.
52. Liu N, Li M, Li X, Meng X, Yang G, et al. (2009) PET-based biodistribution
and radiation dosimetry of epidermal growth factor receptor-selective tracer
11C-PD153035 in humans. J Nucl Med 50: 303–308.
53. Minarini A, Budriesi R, Chiarini A, Leonardi A, Melchiorre C (1998) Search for
alpha(1)-adrenoceptor subtypes selective antagonists: Design, synthesis and
biological activity of cystazosin, an alpha(1D)-adrenoceptor antagonist. Bioorg
Med Chem Lett 8: 1353–1358.
Cardioprotection by PD153035
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10666
